Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 1/2017

05.06.2017 | Original Article

UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis

verfasst von: Xue Zhang, Jia-Fu Yin, Jiao Zhang, Shu-Jia Kong, Hong-Yin Zhang, Xue-Mei Chen

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Irinotecan (IRI) chemotherapy toxicities can be severe, and may result in treatment delay, morbidity and in some rare cases death. Neutropenia is a life-threatening side effect of irinotecan, and UDP glucuronosyltransferases (UGTs) gene polymorphisms could predict the side effects in cancer patients and then reduce IRI-induced toxicity by preventative treatment or a decrease in dose. Both UGT1A1*6 and *28 were reliably demonstrated to be risk factors for IRI-induced neutropenia, with tests for both polymorphisms potentially being particularly useful in Asian cancer patients. However, some researchers reported that UGT1A1*6 could predict IRI-induced toxicities in Asian populations, controversial conclusions still remained. Thus, the association between UGT1A1*6 polymorphisms and IRI-induced severe toxicity in cancer patients is still needed to be explored. Therefore, this study aims to investigate the association between UGT1A1*6 polymorphisms and IRI-related severe neutropenia in cancer patients on a large scale. A total of 12 studies that included 746 wild genotype (G/G) cases and 394 variant genotype (G/A and A/A) cases were included on the basis of inclusion criteria. Then we assessed the methodologies quality; odds ratio (OR), risk difference (RD) and 95% confidence intervals (95% CI) were used to assess the strength of association. Overall, an increased risk of severe neutropenia in cancer patients with UGT1A1*6 polymorphisms was found. Patients with recessive models (GA + AA vs. GG) of UGT1A1*6 showed an increased risk (OR 2.03, 95% CI 1.54–2.68; RD = 0.11, P < 0.001). Specifically, the heterozygous variant of UGT1A1*6 showed an increased risk (OR 1.83, 95% CI 1.36–2.46; RD = 0.09, P < 0.001), and homozygous mutation showed also high risk (OR 2.95, 95% CI 1.83–4.75; RD = 0.18, P < 0.001) for severe neutropenia. Subgroup meta-analysis revealed that for patients harboring both heterozygous and homozygous variants, cancer types, low dose of IRI and the duration of treatment also presented comparably increased risk in suffering severe neutropenia. As for country, in China and Japan, there was a statistically increased severe neutropenia with variant genotype of UGT1A1*6 (China: GA + AA vs. GG, OR 1.83, 95% CI 1.28–2.59; RD = 0.08, P = 0.001; Japan: GA + AA vs. GG, OR 2.39, 95% CI 1.45–3.92; RD = 0.15, P = 0.001). In conclusion, in this meta-analysis, the UGT1A1*6 polymorphisms were associated with an increased risk of IRI-induced neutropenia in cancer patients, and increased incidences of severe neutropenia could be correlated with diverse regions, cancer type, low dose of IRI and the duration of treatment.
Literatur
1.
Zurück zum Zitat Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22(2):229–237CrossRefPubMed Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22(2):229–237CrossRefPubMed
2.
Zurück zum Zitat Ohyanagi F, Horiike A, Okano Y, Satoh Y, Okumura S, Ishikawa Y, Nakagawa K, Horai T, Nishio M (2008) Phase II trial of gemcitabine and irinotecan in previously treated patients with small cell lung cancer. Cancer Chemother Pharmacol 61(3):503–508CrossRefPubMed Ohyanagi F, Horiike A, Okano Y, Satoh Y, Okumura S, Ishikawa Y, Nakagawa K, Horai T, Nishio M (2008) Phase II trial of gemcitabine and irinotecan in previously treated patients with small cell lung cancer. Cancer Chemother Pharmacol 61(3):503–508CrossRefPubMed
3.
Zurück zum Zitat Yamamoto K, Kokawa K, Umesaki N, Nishimura R, Hasegawa K, Konishi I, Saji F, Nishida M, Noguchi H, Takizawa K (2009) Phase I study of combination chemotherapy with irinotecan hydrochloride and nedaplatin for cervical squamous cell carcinoma: Japanese gynecologic oncology group study. Oncol Rep 21(4):1005–1009CrossRefPubMed Yamamoto K, Kokawa K, Umesaki N, Nishimura R, Hasegawa K, Konishi I, Saji F, Nishida M, Noguchi H, Takizawa K (2009) Phase I study of combination chemotherapy with irinotecan hydrochloride and nedaplatin for cervical squamous cell carcinoma: Japanese gynecologic oncology group study. Oncol Rep 21(4):1005–1009CrossRefPubMed
4.
Zurück zum Zitat Takakura S, Takano M, Takahashi F, Saito T, Aoki D, Inaba N, Noda K, Sugiyama T, Ochiai K (2010) Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study. Int J Gynecol Cancer 20(2):240–247CrossRefPubMed Takakura S, Takano M, Takahashi F, Saito T, Aoki D, Inaba N, Noda K, Sugiyama T, Ochiai K (2010) Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study. Int J Gynecol Cancer 20(2):240–247CrossRefPubMed
5.
Zurück zum Zitat Ramesh M, Ahlawat P, Srinivas NR (2010) Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. BMC 24(1):104–123PubMed Ramesh M, Ahlawat P, Srinivas NR (2010) Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. BMC 24(1):104–123PubMed
6.
Zurück zum Zitat Yu M, Tong X, Qi B, Qu H, Dong S, Yu B, Zhang N, Tang N, Wang L, Zhang C (2014) Berberine enhances chemosensitivity to irinotecan in colon cancer via inhibition of NFkappaB. Mol Med Rep 9(1):249–254PubMed Yu M, Tong X, Qi B, Qu H, Dong S, Yu B, Zhang N, Tang N, Wang L, Zhang C (2014) Berberine enhances chemosensitivity to irinotecan in colon cancer via inhibition of NFkappaB. Mol Med Rep 9(1):249–254PubMed
7.
Zurück zum Zitat Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, Ratain MJ (1998) Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Investig 101(4):847–854CrossRefPubMedPubMedCentral Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, Ratain MJ (1998) Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Investig 101(4):847–854CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Cecchin E, Innocenti F, D’Andrea M, Corona G, De Mattia E, Biason P, Buonadonna A, Toffoli G (2009) Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol 27(15):2457–2465CrossRefPubMed Cecchin E, Innocenti F, D’Andrea M, Corona G, De Mattia E, Biason P, Buonadonna A, Toffoli G (2009) Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol 27(15):2457–2465CrossRefPubMed
9.
Zurück zum Zitat Fujita K, Kubota Y, Ishida H, Sasaki Y (2015) Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. World J Gastroenterol 21(43):12234–12248CrossRefPubMedPubMedCentral Fujita K, Kubota Y, Ishida H, Sasaki Y (2015) Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. World J Gastroenterol 21(43):12234–12248CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, Nebert DW (2005) Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genom 15(10):677–685CrossRef Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, Nebert DW (2005) Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genom 15(10):677–685CrossRef
11.
Zurück zum Zitat Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, Jang IJ, Lee DH, Lee JS (2006) Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 24(15):2237–2244CrossRefPubMed Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, Jang IJ, Lee DH, Lee JS (2006) Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 24(15):2237–2244CrossRefPubMed
12.
Zurück zum Zitat Fujita K, Ando Y, Nagashima F, Yamamoto W, Eodo H, Araki K, Kodama K, Miya T, Narabayashi M, Sasaki Y (2007) Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer. Cancer Chemother Pharmacol 60(4):515–522CrossRefPubMed Fujita K, Ando Y, Nagashima F, Yamamoto W, Eodo H, Araki K, Kodama K, Miya T, Narabayashi M, Sasaki Y (2007) Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer. Cancer Chemother Pharmacol 60(4):515–522CrossRefPubMed
13.
Zurück zum Zitat Hazama S, Mishima H, Tsunedomi R, Okuyama Y, Kato T, Takahashi K, Nozawa H, Ando H, Kobayashi M, Takemoto H, Nagata N, Kanekiyo S, Inoue Y, Hamamoto Y, Fujita Y, Hinoda Y, Okayama N, Oba K, Sakamoto J, Oka M (2013) UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan. Cancer Sci 104(12):1662–1669CrossRefPubMed Hazama S, Mishima H, Tsunedomi R, Okuyama Y, Kato T, Takahashi K, Nozawa H, Ando H, Kobayashi M, Takemoto H, Nagata N, Kanekiyo S, Inoue Y, Hamamoto Y, Fujita Y, Hinoda Y, Okayama N, Oba K, Sakamoto J, Oka M (2013) UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan. Cancer Sci 104(12):1662–1669CrossRefPubMed
14.
Zurück zum Zitat Matsuoka A, Ando Y (2015) UGT1A1 genotyping for proper use of irinotecan. Rinsho Byori 63:876–882PubMed Matsuoka A, Ando Y (2015) UGT1A1 genotyping for proper use of irinotecan. Rinsho Byori 63:876–882PubMed
15.
Zurück zum Zitat Sunakawa Y, Ichikawa W, Fujita K, Nagashima F, Ishida H, Yamashita K, Mizuno K, Miwa K, Kawara K, Akiyama Y, Araki K, Yamamoto W, Miya T, Narabayashi M, Ando Y, Hirose T, Saji S, Sasaki Y (2011) UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer. Cancer Chemother Pharmacol 68(2):279–284CrossRefPubMed Sunakawa Y, Ichikawa W, Fujita K, Nagashima F, Ishida H, Yamashita K, Mizuno K, Miwa K, Kawara K, Akiyama Y, Araki K, Yamamoto W, Miya T, Narabayashi M, Ando Y, Hirose T, Saji S, Sasaki Y (2011) UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer. Cancer Chemother Pharmacol 68(2):279–284CrossRefPubMed
16.
Zurück zum Zitat Boyd MA, Srasuebkul P, Ruxrungtham K, Mackenzie PI, Uchaipichat V, Stek M Jr, Lange JM, Phanuphak P, Cooper DA, Udomuksorn W, Miners JO (2006) Relationship between hyperbilirubinaemia and UDP glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. Pharmacogenet Genom 16(5):321–329CrossRef Boyd MA, Srasuebkul P, Ruxrungtham K, Mackenzie PI, Uchaipichat V, Stek M Jr, Lange JM, Phanuphak P, Cooper DA, Udomuksorn W, Miners JO (2006) Relationship between hyperbilirubinaemia and UDP glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. Pharmacogenet Genom 16(5):321–329CrossRef
17.
Zurück zum Zitat Martinez-Balibrea E, Abad A, Martínez-Cardús A, Ginés A, Valladares M, Navarro M, Aranda E, Marcuello E, Benavides M, Massutí B, Carrato A, Layos L, Manzano JL, Moreno V (2010) UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. Br J Cancer 103(4):581–589CrossRefPubMedPubMedCentral Martinez-Balibrea E, Abad A, Martínez-Cardús A, Ginés A, Valladares M, Navarro M, Aranda E, Marcuello E, Benavides M, Massutí B, Carrato A, Layos L, Manzano JL, Moreno V (2010) UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. Br J Cancer 103(4):581–589CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Takano M, Kato M, Yoshikawa T, Sasaki N, Hirata J, Furuya K, Takahashi M, Yokota H, Kino N, Horie K, Goto T, Fujiwara K, Ishii K, Kikuchi Y, Kita T (2009) Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study. Oncology 76(5):315–321CrossRefPubMed Takano M, Kato M, Yoshikawa T, Sasaki N, Hirata J, Furuya K, Takahashi M, Yokota H, Kino N, Horie K, Goto T, Fujiwara K, Ishii K, Kikuchi Y, Kita T (2009) Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study. Oncology 76(5):315–321CrossRefPubMed
19.
Zurück zum Zitat Fukui T, Mitsufuji H, Kubota M, Inaoka H, Hirose M, Iwabuchi K, Masuda N, Kobayashi H (2011) Prevalence of topoisomerase I genetic mutations and UGT1A1 polymorphisms associated with irinotecan in individuals of Asian descent. Oncol Lett 2(5):923–928PubMedPubMedCentral Fukui T, Mitsufuji H, Kubota M, Inaoka H, Hirose M, Iwabuchi K, Masuda N, Kobayashi H (2011) Prevalence of topoisomerase I genetic mutations and UGT1A1 polymorphisms associated with irinotecan in individuals of Asian descent. Oncol Lett 2(5):923–928PubMedPubMedCentral
20.
Zurück zum Zitat Fukui T, Mitsufuji H, Kubota M, Inaoka H, Hirose M, Iwabuchi K, Masuda N, Kobayashi H (2002) Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 12(5):725–733 Fukui T, Mitsufuji H, Kubota M, Inaoka H, Hirose M, Iwabuchi K, Masuda N, Kobayashi H (2002) Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 12(5):725–733
21.
Zurück zum Zitat Kaniwa N, Kurose K, Jinno H, Tanaka-Kagawa T, Saito Y, Saeki M, Sawada J, Tohkin M, Hasegawa R (2005) Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C>T (P229L) found in an African–American. Drug Metab Dispos 33(3):458–465CrossRefPubMed Kaniwa N, Kurose K, Jinno H, Tanaka-Kagawa T, Saito Y, Saeki M, Sawada J, Tohkin M, Hasegawa R (2005) Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C>T (P229L) found in an African–American. Drug Metab Dispos 33(3):458–465CrossRefPubMed
22.
Zurück zum Zitat Marques SC, Ikediobi ON (2010) The clinical application of UGT1A1 pharmacogenetic testing: gene-environment interactions. Hum Genom 4(4):238–249 Marques SC, Ikediobi ON (2010) The clinical application of UGT1A1 pharmacogenetic testing: gene-environment interactions. Hum Genom 4(4):238–249
23.
Zurück zum Zitat Park SR, Kong SY, Rhee J, Park YI, Ryu KW, Lee JH, Kim YW, Choi IJ, Kim CG, Lee JY, Cho SJ, Kim NK (2011) Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results. Ann Oncol 22(4):890–896CrossRefPubMed Park SR, Kong SY, Rhee J, Park YI, Ryu KW, Lee JH, Kim YW, Choi IJ, Kim CG, Lee JY, Cho SJ, Kim NK (2011) Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results. Ann Oncol 22(4):890–896CrossRefPubMed
24.
Zurück zum Zitat Atasilp C, Chansriwong P, Sirachainan E, Reungwetwattana T, Chamnanphon M, Puangpetch A, Wongwaisayawan S, Sukasem C (2016) Correlation of UGT1A1*28 and *6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients. Drug Metab Pharmacokinet 31(1):90–94CrossRefPubMed Atasilp C, Chansriwong P, Sirachainan E, Reungwetwattana T, Chamnanphon M, Puangpetch A, Wongwaisayawan S, Sukasem C (2016) Correlation of UGT1A1*28 and *6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients. Drug Metab Pharmacokinet 31(1):90–94CrossRefPubMed
25.
Zurück zum Zitat Jo JC, Lee JL, Ryu MH, Chang HM, Kim M, Lee HJ, Kim HS, Shin JG, Kim TW, Kang YK (2012) Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer. Br J Cancer 106:1591–1597CrossRefPubMedPubMedCentral Jo JC, Lee JL, Ryu MH, Chang HM, Kim M, Lee HJ, Kim HS, Shin JG, Kim TW, Kang YK (2012) Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer. Br J Cancer 106:1591–1597CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Zhou CF, Ma T, Su Y, Ye ZB, Ji J, Yu YY, Zhang J, Liu BY, Zhu ZG (2013) UGT1A1 gene polymorphisms and the toxicities of FOLFIRI in Chinese Han patients with gastrointestinal cancer. Anticancer Agents Med Chem 13:235–241CrossRefPubMed Zhou CF, Ma T, Su Y, Ye ZB, Ji J, Yu YY, Zhang J, Liu BY, Zhu ZG (2013) UGT1A1 gene polymorphisms and the toxicities of FOLFIRI in Chinese Han patients with gastrointestinal cancer. Anticancer Agents Med Chem 13:235–241CrossRefPubMed
27.
Zurück zum Zitat Wang Y, Shen L, Xu N, Wang JW, Jiao SC, Liu ZY, Xu JM (2012) UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil. World J Gastroenterol 18(45):6635–6644CrossRefPubMedPubMedCentral Wang Y, Shen L, Xu N, Wang JW, Jiao SC, Liu ZY, Xu JM (2012) UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil. World J Gastroenterol 18(45):6635–6644CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Park SR, Kong SY, Rhee J, Park YI, Ryu KW, Lee JH, Kim YW, Choi IJ, Kim CG, Lee JY, Cho SJ, Kim NK (2010) Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results. Ann Oncol 22(4):890–896CrossRefPubMed Park SR, Kong SY, Rhee J, Park YI, Ryu KW, Lee JH, Kim YW, Choi IJ, Kim CG, Lee JY, Cho SJ, Kim NK (2010) Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results. Ann Oncol 22(4):890–896CrossRefPubMed
29.
Zurück zum Zitat Zintzaras E, Ioannidis JP (2005) Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 28(2):123–137CrossRefPubMed Zintzaras E, Ioannidis JP (2005) Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 28(2):123–137CrossRefPubMed
30.
31.
Zurück zum Zitat Duval S, Tweedie R (2000) A nonparametric “Trim and Fill” method of accounting for publication bias in meta-analysis. Biometrics 56(2):455–463CrossRefPubMed Duval S, Tweedie R (2000) A nonparametric “Trim and Fill” method of accounting for publication bias in meta-analysis. Biometrics 56(2):455–463CrossRefPubMed
32.
Zurück zum Zitat Xiao XG, Xia S, Zou M, Mei Q, Zhou L, Wang SJ, Chen Y (2015) The relationship between UGT1A1 gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancer. Onco Targets Ther 3(8):3575–3583CrossRef Xiao XG, Xia S, Zou M, Mei Q, Zhou L, Wang SJ, Chen Y (2015) The relationship between UGT1A1 gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancer. Onco Targets Ther 3(8):3575–3583CrossRef
33.
Zurück zum Zitat Yang C, Liu Y, Xi WQ, Zhou CF, Jiang JL, Ma T, Ye ZB, Zhang J, Zhu ZG (2015) Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens. Drug Des Devel Ther 17(9):3677–3683 Yang C, Liu Y, Xi WQ, Zhou CF, Jiang JL, Ma T, Ye ZB, Zhang J, Zhu ZG (2015) Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens. Drug Des Devel Ther 17(9):3677–3683
34.
Zurück zum Zitat Gao J, Zhou J, Li Y, Lu M, Jia R, Shen L (2013) UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients. Med Oncol 30(3):604CrossRefPubMed Gao J, Zhou J, Li Y, Lu M, Jia R, Shen L (2013) UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients. Med Oncol 30(3):604CrossRefPubMed
35.
Zurück zum Zitat Onoue M, Terada T, Kobayashi M, Katsura T, Matsumoto S, Yanagihara K, Nishimura T, Kanai M, Teramukai S, Shimizu A, Fukushima M, Inui K (2009) UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol 14(2):136–142CrossRefPubMed Onoue M, Terada T, Kobayashi M, Katsura T, Matsumoto S, Yanagihara K, Nishimura T, Kanai M, Teramukai S, Shimizu A, Fukushima M, Inui K (2009) UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol 14(2):136–142CrossRefPubMed
36.
Zurück zum Zitat Gao J, Zhou J, Li Y, Peng Z, Li Y, Wang X, Shen L (2013) Associations between UGT1A1*6/*28 polymorphisms and irinotecan induced severe toxicity in Chinese gastric or esophageal cancer patients. Med Oncol 30(3):630–634CrossRefPubMed Gao J, Zhou J, Li Y, Peng Z, Li Y, Wang X, Shen L (2013) Associations between UGT1A1*6/*28 polymorphisms and irinotecan induced severe toxicity in Chinese gastric or esophageal cancer patients. Med Oncol 30(3):630–634CrossRefPubMed
37.
Zurück zum Zitat Xu C, Tang X, Qu Y, Keyoumu S, Zhou N, Tang Y (2016) UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 78(1):119–130CrossRefPubMed Xu C, Tang X, Qu Y, Keyoumu S, Zhou N, Tang Y (2016) UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 78(1):119–130CrossRefPubMed
38.
Zurück zum Zitat Nakamura Y, Soda H, Oka M, Kinoshita A, Fukuda M, Fukuda M, Takatani H, Nagashima S, Soejima Y, Kasai T, Nakatomi K, Masuda N, Tsukamoto K, Kohno S (2011) Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia. J Thorac Oncol 6(1):121–127CrossRefPubMed Nakamura Y, Soda H, Oka M, Kinoshita A, Fukuda M, Fukuda M, Takatani H, Nagashima S, Soejima Y, Kasai T, Nakatomi K, Masuda N, Tsukamoto K, Kohno S (2011) Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia. J Thorac Oncol 6(1):121–127CrossRefPubMed
39.
Zurück zum Zitat Choi YH, Kim TW, Kim KP, Lee SS, Hong YS, Ryu MH, Lee JL, Chang HM, Ryoo BY, Kim HS, Shin JG, Kang YK (2012) A phase II study of clinical outcomes of 3-week cycles of irinotecan and S-1 in patients with previously untreated metastatic colorectal cancer: influence of the UGT1A1 and CYP2A6 polymorphisms on clinical activity. Oncology 82(5):290–297CrossRefPubMed Choi YH, Kim TW, Kim KP, Lee SS, Hong YS, Ryu MH, Lee JL, Chang HM, Ryoo BY, Kim HS, Shin JG, Kang YK (2012) A phase II study of clinical outcomes of 3-week cycles of irinotecan and S-1 in patients with previously untreated metastatic colorectal cancer: influence of the UGT1A1 and CYP2A6 polymorphisms on clinical activity. Oncology 82(5):290–297CrossRefPubMed
40.
Zurück zum Zitat Satoh T, Ura T, Yamada Y, Yamazaki K, Tsujinaka T, Munakata M, Nishina T, Okamura S, Esaki T, Sasaki Y, Koizumi W, Kakeji Y, Ishizuka N, Hyodo I, Sakata Y (2011) Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms. Cancer Sci 102(10):1868–1873CrossRefPubMed Satoh T, Ura T, Yamada Y, Yamazaki K, Tsujinaka T, Munakata M, Nishina T, Okamura S, Esaki T, Sasaki Y, Koizumi W, Kakeji Y, Ishizuka N, Hyodo I, Sakata Y (2011) Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms. Cancer Sci 102(10):1868–1873CrossRefPubMed
41.
Zurück zum Zitat Okuyama Y, Hazama S, Nozawa H, Kobayashi M, Takahashi K, Fujikawa K, Kato T, Nagata N, Kimura H, Oba K, Sakamoto J, Mishima H (2011) Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms. Jpn J Clin Oncol 41(4):477–482CrossRefPubMed Okuyama Y, Hazama S, Nozawa H, Kobayashi M, Takahashi K, Fujikawa K, Kato T, Nagata N, Kimura H, Oba K, Sakamoto J, Mishima H (2011) Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms. Jpn J Clin Oncol 41(4):477–482CrossRefPubMed
42.
Zurück zum Zitat Wang W, Huang J, Tao Y, Lyu X, Yang L, Wu D, Tian Y (2016) Phase II and UGT1A1 polymorphism study of two different irinotecan dosages combined with cisplatin as first-line therapy for advanced gastric cancer. Chemotherapy 61(4):197–203CrossRefPubMed Wang W, Huang J, Tao Y, Lyu X, Yang L, Wu D, Tian Y (2016) Phase II and UGT1A1 polymorphism study of two different irinotecan dosages combined with cisplatin as first-line therapy for advanced gastric cancer. Chemotherapy 61(4):197–203CrossRefPubMed
43.
Zurück zum Zitat Cheng L, Li M, Hu J, Ren W, Xie L, Sun ZP, Liu BR, Xu GX, Dong XL, Qian XP (2014) UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians. Cancer Chemother Pharmacol 73(3):551–560CrossRefPubMed Cheng L, Li M, Hu J, Ren W, Xie L, Sun ZP, Liu BR, Xu GX, Dong XL, Qian XP (2014) UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians. Cancer Chemother Pharmacol 73(3):551–560CrossRefPubMed
44.
Zurück zum Zitat Han FF, Guo CL, Yu D, Zhu J, Gong LL, Li GR, Lv YL, Liu H, An GY, Liu LH (2014) Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients. Cancer Chemother Pharmacol 73(4):779–788CrossRefPubMed Han FF, Guo CL, Yu D, Zhu J, Gong LL, Li GR, Lv YL, Liu H, An GY, Liu LH (2014) Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients. Cancer Chemother Pharmacol 73(4):779–788CrossRefPubMed
45.
Zurück zum Zitat Campbell JM, Stephenson MD, Bateman E, Peters MD, Keefe DM, Bowen JM (2016) Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Pharmacogenom J. doi:10.1038/tpj.2016.58 Campbell JM, Stephenson MD, Bateman E, Peters MD, Keefe DM, Bowen JM (2016) Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Pharmacogenom J. doi:10.​1038/​tpj.​2016.​58
46.
Zurück zum Zitat Jinno H, Tanaka-Kagawa T, Hanioka N, Saeki M, Ishida S, Nishimura T, Ando M, Saito Y, Ozawa S, Sawada J (2003) Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Drug Metab Dispos 31(1):108–113CrossRefPubMed Jinno H, Tanaka-Kagawa T, Hanioka N, Saeki M, Ishida S, Nishimura T, Ando M, Saito Y, Ozawa S, Sawada J (2003) Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Drug Metab Dispos 31(1):108–113CrossRefPubMed
47.
Zurück zum Zitat Gagne JF, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C (2002) Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 62(3):608–617CrossRefPubMed Gagne JF, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C (2002) Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 62(3):608–617CrossRefPubMed
48.
Zurück zum Zitat Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, Kaniwa N, Sawada J, Hamaguchi T, Yamamoto N, Shirao K, Yamada Y, Ohmatsu H, Kubota K, Yoshida T, Ohtsu A, Saijo N (2007) Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genom 17(7):497–504CrossRef Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, Kaniwa N, Sawada J, Hamaguchi T, Yamamoto N, Shirao K, Yamada Y, Ohmatsu H, Kubota K, Yoshida T, Ohtsu A, Saijo N (2007) Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genom 17(7):497–504CrossRef
49.
Zurück zum Zitat Pharmaceutical and Food Safety Bureau MoH, Labour and Welfare (2008) Pharmaceuticals and medical devices safety information. Pharmaceutical and food safety Bureau MoH, labour and welfare, Japan ed., vol. No. 248 Pharmaceutical and Food Safety Bureau, Ministry of health, Labour and Welfare Pharmaceutical and Food Safety Bureau MoH, Labour and Welfare (2008) Pharmaceuticals and medical devices safety information. Pharmaceutical and food safety Bureau MoH, labour and welfare, Japan ed., vol. No. 248 Pharmaceutical and Food Safety Bureau, Ministry of health, Labour and Welfare
50.
Zurück zum Zitat Association between UGT1A1 variant alleles and irinotecan induced severe neutropenia (2010). In: Authority HS (ed) vol 12. Health Products Regulation Group, HSA and the HSA Pharmacovigilance Advisory Committee Association between UGT1A1 variant alleles and irinotecan induced severe neutropenia (2010). In: Authority HS (ed) vol 12. Health Products Regulation Group, HSA and the HSA Pharmacovigilance Advisory Committee
Metadaten
Titel
UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis
verfasst von
Xue Zhang
Jia-Fu Yin
Jiao Zhang
Shu-Jia Kong
Hong-Yin Zhang
Xue-Mei Chen
Publikationsdatum
05.06.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 1/2017
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-017-3344-3

Weitere Artikel der Ausgabe 1/2017

Cancer Chemotherapy and Pharmacology 1/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.